BIOA BIOAGE LABS INC.

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.

TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts

PR: Chris Patil,

IR: Dov Goldstein,

Partnering:

Web:



EN
20/02/2025

Underlying

BIOABIOAGE LABS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOAGE LABS INC.

 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in ...

August 20, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Tria...

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated robust weight loss in preclinical models, both as monotherapy and in combination with GLP-1 receptor agonists Initial Phase 1 SAD data anticipated by end of 2025, with top-line readout of obesity study by end of 2026 EMERYVILLE, Cal...

August 15, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides...

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery platform through molecular profiling of 17,000+ samples from leading European HUNT Biobank EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) --  BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Ob...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company devel...

June 21, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Expands Drug Discovery Platform with Data from Leading Eur...

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targetin...

June 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch